J E Lupatsch
A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland
Panje C, Schwenkglenks M, Gautschi O, Plasswilm L, Aebersold D, Dedes K, Lorez M, Pardo E, Barbier M, Lupatsch J, Swiss Group for Clinical Cancer Research (SAKK). A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland. Ann Oncol 2020; 31:501-506.
16.01.2020A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland
16.01.2020Ann Oncol 2020; 31:501-506
Panje Cédric, Schwenkglenks M, Gautschi O, Plasswilm Ludwig, Aebersold D M, Dedes K J, Lorez M, Pardo E, Barbier M, Lupatsch J E, Swiss Group for Clinical Cancer Research (SAKK)
Cost-effectiveness of nivolumab in the treatment of head and neck cancer
Hirschmann A, Lupatsch J, Schwenkglenks M, Panje C, Matter-Walstra K, Espeli V, Dedes K, Siano M, Swiss Group of Clinical Cancer Research (SAKK). Cost-effectiveness of nivolumab in the treatment of head and neck cancer. Oral Oncol 2018; 87:104-110.
30.10.2018Cost-effectiveness of nivolumab in the treatment of head and neck cancer
30.10.2018Oral Oncol 2018; 87:104-110
Hirschmann A, Lupatsch J E, Schwenkglenks M, Panje Cédric, Matter-Walstra K, Espeli V, Dedes K J, Siano Marco, Swiss Group of Clinical Cancer Research (SAKK)